Clearance, as assessed by a clinician at any · infantile haemangiomas (strawberry birthmarks) of the skin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
A subjective measure of improvement, as assessed by the parent or child, at any · infantile haemangiomas (strawberry birthmarks) of the skin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Improvement in acne severity assessed by a decrease in total inflammatory lesion count, measured in participants who were treated for a minimum period of 16 weeks (Changes from baseline in total inflammatory lesion count and number of participants... · participants with moderate and severe acne
1 finding from 1 review
Intervention not reported
Frequency of serious adverse effects 20 to 24 weeks · participants with moderate and severe acne
It is very uncertain whether the intervention changes frequency of serious adverse effects 20 to 24 weeks (very low certainty).
1 finding from 1 review
Intervention not reported
Improvement in acne severity assessed by physician's global evaluation 20 to 24 weeks · participants with moderate and severe acne
1 finding from 1 review
Overall survival† · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to lower overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.42 [0.37, 0.48]
418 participants
High
Progression‐free survival · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
HR 0.76 [0.63, 0.92]
502 participants
Moderate
Tumour response · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in tumour response compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.28 [0.92, 1.77]
1157 participants
Moderate
Toxicity (≥ G3) · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.69 [1.19, 2.42]
1142 participants
Moderate
Overall survival · people with cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies with leads to lower progression‐free survival† compared with without anti‐PD1 monoclonal antibodies (high certainty).
1 finding from 1 review
HR 0.4 [0.35, 0.46]
738 participants
High
Tumour response · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies with leads to higher tumour response compared with without anti‐PD1 monoclonal antibodies (high certainty).
1 finding from 1 review
RR 3.5 [2.07, 5.92]
738 participants
High
Toxicity (≥ G3) · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies with showed no clear difference in toxicity (≥ G3) compared with without anti‐PD1 monoclonal antibodies (low certainty).
1 finding from 1 review
RR 1.57 [0.85, 2.92]
764 participants
Low
Overall survival† · people with cutaneous melanoma
BRAF inhibitors leads to lower overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.4 [0.28, 0.57]
925 participants
High
Progression‐free survival · people with cutaneous melanoma
BRAF inhibitors leads to lower progression‐free survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.27 [0.21, 0.34]
925 participants
High
Tumour response · people with cutaneous melanoma
BRAF inhibitors leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
RR 6.78 [4.84, 9.49]
925 participants
High
Progression‐free survival · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
HR 0.49 [0.39, 0.61]
957 participants
Moderate
Toxicity (≥ G3) · people with cutaneous melanoma
BRAF inhibitors showed no clear difference in toxicity (≥ G3) compared with chemotherapy (low certainty).
1 finding from 1 review
RR 1.27 [0.48, 3.33]
408 participants
Low
Overall survival† · people with cutaneous melanoma
MEK inhibitors showed no clear difference in overall survival† compared with chemotherapy (low certainty).
1 finding from 1 review
HR 0.85 [0.58, 1.25]
496 participants
Low
Progression‐free survival · people with cutaneous melanoma
MEK inhibitors probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
HR 0.58 [0.42, 0.8]
496 participants
Moderate